中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2013
Turn off MathJax
Article Contents

Clinical efficacy of cyclophosphamide in treatment of primary sclerosing cholangitis

DOI: 10.3969/j.issn.1001-5256.2013.12.014
  • Received Date: 2013-01-16
  • Published Date: 2013-12-20
  • Objective To investigate the clinical efficacy of cyclophosphamide in the treatment of primary sclerosing cholangitis ( PSC) .Methods Twenty-four patients with PSC who received treatment in the department of gastroenterology in our hospital from January 2004 to December 2012 were selected as subjects and divided into observation group ( n = 13) and control group ( n = 11) . The control group was treated with ursodesoxycholic acid, while the observation group with ursodesoxycholic acid plus cyclophosphamide. After four weeks of treatment, clinical outcome, changes in serum bilirubin levels, and adverse reactions were compared between the two groups. Categorical data were analyzed by Fisher exact probability test, and continuous data by independent-samples t test and paired-samples t test. Results Compared with the control group, the observation group had a significantly higher response rate ( 84. 62% vs 45. 45%, P = 0. 0489) , significantly more improvements in serum total and direct bilirubin levels ( t = 12. 45, P < 0. 001; t = 5. 60, P < 0. 001) , and a nonsignificantly higher incidence of adverse reactions ( 23. 08% vs 18. 18%, P = 0. 741) . Conclusion Cyclophosphamide has significant clinical efficacy and tolerable incidence of adverse events in the treatment of PSC, so it is worthy of application in clinical treatment.

     

  • loading
  • [1]BAMBHA K, KIM WR, TALWALKAR J, et al.Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community[J].Gastroenterology, 2003, 125 (5) :1364-1369.
    [2]TAKIKAWA H, MANABE T.Primary sclerosing cholangitis in Japan-analysis of 192 cases[J].J Gastroenterol, 1997, 32 (1) :134-137.
    [3]ARENAS-GAMBOA AM, BEARSS JJ, HUBBARD GB, et al.Sclerosing cholangitis in baboons (Papio spp) resembling primary sclerosing cholangitis of humans[J].Vet Pathol, 2012, 49 (3) :524-527.
    [4]QU Y, XU YM, LU LG.Current progress in understanding of cholestasis and autoimmune liver diseases-Meeting review about 1st symposium on cholestasis and autoimmune liver disease[J].J Clin Hepatol, 2011, 27 (2) :222-225. (in Chinese) 曲颖, 徐铭益, 陆伦根.胆汁淤积和自身免疫性肝病研究进展暨“第一届胆汁淤积和自身免疫性肝病专题学术研讨会”纪要[J].临床肝胆病杂志, 2011, 27 (2) :222-225.
    [5]POUPON R.Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases:an overview of their mechanisms of action[J].Clin Res Hepatol Gastroenterol, 2012, 36 (Suppl 1) :s3-s12.
    [6]ZHAO YJ, SUN JY.The therapeutic effect of ursodeoxycholic acid capsules in patients with primary biliary cirrhosis[J].J Clin Hepatol, 2010, 26 (4) :432-433. (in Chinese) 赵艳娟, 孙吉莹.熊去氧胆酸 (优思弗) 治疗原发性胆汁性肝硬化的临床疗效观察[J].临床肝胆病杂志, 2010, 26 (4) :432-433.
    [7]LINDOR KD, KOWDLEY KV, LUKETIC VA, et al.High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis[J].Hepatology, 2009, 50 (3) :808-814.
    [8]IBRAHIM SH, LINDOR KD.Current management of primary sclerosing cholangitis in pediatric patients[J].Pediatr Drugs, 2011, 13 (2) :87-95.
    [9]STANKIEWICZ JM, KOLB H, KARNI A, et al.Role of immunosuppressive therapy for the treatment of multiple sclerosis[J].Neurotherapeutics, 2013, 10 (1) :77-88.
    [10]OH DC, NG TM, HO J, et al.Systemic lupus erythematosus with concurrent protein-losing enteropathy and primary sclerosing cholangitis:a unique association[J].Lupus, 2006, 15 (2) :102-104.
    [11]CHEN M, LI H, LI XY, et al.Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy:a multicenter randomized controlled trial[J].Am J Med Sci, 2010, 339 (3) :233-238.
    [12]MALVICINI M, PICCIONI F, BAYO J, et al.Chemoimmunotherapy for advanced gastrointestinal carcinomas:A successful combination of gene therapy and cyclophosphamide[J].Oncoimmunology, 2012, 1 (9) :1626-1628.
    [13]RAZA M, ALGHASHAM AA.Desferrioxamine protects against toxic damage to liver and kidney induced by cyclophosphamide[J].Int J Health Sci (Qassim) , 2011, 5 (2 Suppl 1) :15-17.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2746) PDF downloads(570) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return